Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:02
07/28/20
07/28
09:02
07/28/20
09:02
KODK

Eastman Kodak

$2.62 /

+0.51 (+24.17%)

, OSMT

Osmotica Pharmaceuticals

$5.34 /

-0.08 (-1.48%)

, PFE

Pfizer

$37.59 /

-0.08 (-0.21%)

, RTX

Raytheon Technologies

$61.12 /

-0.97 (-1.56%)

, SPGI

S&P Global

$351.39 /

+1.665 (+0.48%)

, SHW

Sherwin-Williams

$626.70 /

+6.39 (+1.03%)

, PII

Polaris

$97.97 /

+2.525 (+2.65%)

, MCD

McDonald's

$201.23 /

+2.47 (+1.24%)

, MMM

3M

$163.31 /

+3.555 (+2.23%)

, CNC

Centene

$67.21 /

-0.325 (-0.48%)

, HOG

Harley-Davidson

$29.27 /

+0.2 (+0.69%)

, NXPI

NXP Semiconductors

$120.29 /

+4.62 (+3.99%)

, CRMD

CorMedix

$5.96 /

+0.13 (+2.23%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
SPGI S&P Global
$351.39 /

+1.665 (+0.48%)

SHW Sherwin-Williams
$626.70 /

+6.39 (+1.03%)

RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

PII Polaris
$97.97 /

+2.525 (+2.65%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

MMM 3M
$163.31 /

+3.555 (+2.23%)

MCD McDonald's
$201.23 /

+2.47 (+1.24%)

KODK Eastman Kodak
$2.62 /

+0.51 (+24.17%)

HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

CRMD CorMedix
$5.96 /

+0.13 (+2.23%)

CNC Centene
$67.21 /

-0.325 (-0.48%)

KODK Eastman Kodak
$2.62 /

+0.51 (+24.17%)

OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
PFE Pfizer
$37.59 /

-0.08 (-0.21%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
07/14/20 Mizuho
IPR not likely to impact uniQure's ability to commercialize AMT-061, says Mizuho
RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

07/17/20 Susquehanna
Raytheon Technologies price target raised to $74 from $66 at Susquehanna
07/17/20 RBC Capital
Raytheon Technologies price target lowered to $66 from $69 at RBC Capital
07/10/20 Vertical Research
Raytheon Technologies upgraded to Buy from Hold at Vertical Research
07/01/20 Stifel
Jacobs secures 'key strategic, highly competitive' takeaway win, says Stifel
SPGI S&P Global
$351.39 /

+1.665 (+0.48%)

07/08/20
Fly Intel: Top five analyst upgrades
07/08/20 Goldman Sachs
S&P Global upgraded to Conviction Buy from Buy at Goldman Sachs
06/08/20 BMO Capital
S&P Global price target raised to $365 from $322 at BMO Capital
05/29/20 Credit Suisse
S&P Global initiated with an Outperform at Credit Suisse
SHW Sherwin-Williams
$626.70 /

+6.39 (+1.03%)

06/24/20 Baird
Sherwin-Williams price target raised to $650 from $550 at Baird
06/23/20 Wells Fargo
Sherwin-Williams price target raised to $640 from $600 at Wells Fargo
06/23/20 Deutsche Bank
Sherwin-Williams price target raised to $675 from $625 at Deutsche Bank
06/23/20 BMO Capital
Sherwin-Williams price target raised to $590 from $550 at BMO Capital
PII Polaris
$97.97 /

+2.525 (+2.65%)

07/06/20 Wedbush
Polaris added to Best Ideas List at Wedbush
06/18/20 BMO Capital
Polaris price target raised to $84 from $70 at BMO Capital
06/16/20 Truist
SunTrust raises 2020 marine retail volume forecast to down 5% to flat
06/03/20 Lake Street
Polaris price target raised to $107 from $82 at Lake Street
MCD McDonald's
$201.23 /

+2.47 (+1.24%)

07/27/20 Stephens
McDonald's, Domino's among restaurant stocks to own now, says Stephens
07/15/20 Longbow
Longbow remains confident in domestic recovery at McDonald's after checks
06/24/20 BMO Capital
McDonald's price target raised to $220 from $215 at BMO Capital
06/24/20 JPMorgan
McDonald's price target raised to $204 from $180 at JPMorgan
MMM 3M
$163.31 /

+3.555 (+2.23%)

04/29/20 Credit Suisse
3M price target raised to $180 from $165 at Credit Suisse
04/29/20 RBC Capital
3M price target raised to $148 from $143 at RBC Capital
03/30/20
Fly Intel: Top five analyst downgrades
03/30/20 Gordon Haskett
3M downgraded to Underperform from Hold at Gordon Haskett
CNC Centene
$67.21 /

-0.325 (-0.48%)

07/01/20 SVB Leerink
Centene reinstated with an Outperform at SVB Leerink
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
04/29/20 Oppenheimer
Centene price target raised to $90 from $83 at Oppenheimer
04/29/20 Piper Sandler
Centene selloff yesterday a buying opportunity, says Piper Sandler
HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

07/16/20
Fly Intel: Top five analyst upgrades
07/16/20 Wedbush
Wedbush upgrades Harley-Davidson to Buy on increase in demand
07/16/20 Wedbush
Harley-Davidson upgraded to Outperform from Neutral at Wedbush
07/15/20
Fly Intel: Top five analyst upgrades
NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

07/27/20 Needham
NXP Semiconductors price target raised to $140 from $125 at Needham
07/17/20 Deutsche Bank
NXP Semiconductors price target raised to $135 from $115 at Deutsche Bank
07/13/20 Raymond James
NXP Semiconductors price target raised to $130 from $115 at Raymond James
06/08/20
Fly Intel: Top five analyst upgrades
CRMD CorMedix
$5.96 /

+0.13 (+2.23%)

12/18/19 B. Riley FBR
B. Riley FBR starts CorMedix with Buy rating, $15 price target
12/18/19 B. Riley FBR
CorMedix initiated with a Buy at B. Riley FBR
SPGI S&P Global
$351.39 /

+1.665 (+0.48%)

SHW Sherwin-Williams
$626.70 /

+6.39 (+1.03%)

RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

PII Polaris
$97.97 /

+2.525 (+2.65%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

MMM 3M
$163.31 /

+3.555 (+2.23%)

MCD McDonald's
$201.23 /

+2.47 (+1.24%)

HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

CRMD CorMedix
$5.96 /

+0.13 (+2.23%)

CNC Centene
$67.21 /

-0.325 (-0.48%)

  • 28
    Jul
  • 14
    Jul
  • 09
    Jan
SPGI S&P Global
$351.39 /

+1.665 (+0.48%)

SHW Sherwin-Williams
$626.70 /

+6.39 (+1.03%)

RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

MMM 3M
$163.31 /

+3.555 (+2.23%)

MCD McDonald's
$201.23 /

+2.47 (+1.24%)

KODK Eastman Kodak
$2.62 /

+0.51 (+24.17%)

HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

CNC Centene
$67.21 /

-0.325 (-0.48%)

SPGI S&P Global
$351.39 /

+1.665 (+0.48%)

SHW Sherwin-Williams
$626.70 /

+6.39 (+1.03%)

RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

MMM 3M
$163.31 /

+3.555 (+2.23%)

MCD McDonald's
$201.23 /

+2.47 (+1.24%)

KODK Eastman Kodak
$2.62 /

+0.51 (+24.17%)

HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

CNC Centene
$67.21 /

-0.325 (-0.48%)

RTX Raytheon Technologies
$61.12 /

-0.97 (-1.56%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

NXPI NXP Semiconductors
$120.29 /

+4.62 (+3.99%)

MMM 3M
$163.31 /

+3.555 (+2.23%)

MCD McDonald's
$201.23 /

+2.47 (+1.24%)

HOG Harley-Davidson
$29.27 /

+0.2 (+0.69%)

CNC Centene
$67.21 /

-0.325 (-0.48%)

Hot Stocks
Osmotica, RVL Pharmaceuticals enter license agreement in Japan » 07:15
07/28/20
07/28
07:15
07/28/20
07:15
OSMT

Osmotica Pharmaceuticals

$5.34 /

-0.08 (-1.48%)

Santen Pharmaceutical Co.…

Santen Pharmaceutical Co. and RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced an exclusive license agreement covering the development, registration, and commercialization rights in Japan, China, and other Asian countries as well as EMEA countries to RVL-1201, oxymetazoline hydrochloride ophthalmic solution 0.1%, which is the first and only ophthalmic formulation approved by the U.S. FDA for the treatment of acquired blepharoptosis or ptosis in adults. Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement. RVL-1201 is a novel, once-daily ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, which when administered to the eye, is believed to selectively target Muller's muscle and elevate the upper eyelid. RVL-1201, was approved on July 8, 2020 under the brand name UPNEEQ in the United States. Under the terms of the licensing agreement, Osmotica will receive up to $89M in upfront and milestone payments, not including future royalties on sales in Santen's territories. Osmotica will receive an upfront cash payment of $25M and up to an additional $64M in cash milestone payments based on regulatory and sales achievements in Santen's territories. Osmotica is also entitled to royalty payments on sales of RVL-1201 in Japan, China, and other Asian countries as well as EMEA.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

  • 14
    Jul
  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$5.34 /

-0.08 (-1.48%)

Hot Stocks
Osmotica Pharmaceuticals: FDA user fee goal date of 12/29 for arbaclofen » 06:52
07/20/20
07/20
06:52
07/20/20
06:52
OSMT

Osmotica Pharmaceuticals

$6.34 /

+0.37 (+6.20%)

Osmotica Pharmaceuticals,…

Osmotica Pharmaceuticals, through its subsidiary Osmotica Pharmaceutical U.S., announced that the U.S. Food and Drug Administration considers the company's re-submission to its new drug application for arbaclofen extended release tablets a complete, class 2 response to the July 9, 2016, action letter; the user fee goal date is December 29, 2020.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$6.34 /

+0.37 (+6.20%)

OSMT Osmotica Pharmaceuticals
$6.34 /

+0.37 (+6.20%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
OSMT Osmotica Pharmaceuticals
$6.34 /

+0.37 (+6.20%)

  • 14
    Jul
  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$6.34 /

+0.37 (+6.20%)

On The Fly
Fly Intel: Pre-market Movers » 09:02
07/14/20
07/14
09:02
07/14/20
09:02
KPTI

Karyopharm

$17.83 /

-1.33 (-6.94%)

, TSLA

Tesla

$1,493.85 /

-53.69 (-3.47%)

, FIT

Fitbit

$6.64 /

-0.175 (-2.57%)

, HBI

Hanesbrands

$11.47 /

+0.035 (+0.31%)

, INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, EQ

Equillium

$27.05 /

+23.95 (+772.58%)

, VRCA

Verrica Pharmaceuticals

$8.80 /

-0.71 (-7.47%)

, SPOT

Spotify

$261.11 /

-17.08 (-6.14%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, JPM

JPMorgan

$97.66 /

+1.35 (+1.40%)

, C

Citi

$52.25 /

-0.39 (-0.74%)

, WFC

Wells Fargo

$25.43 /

-0.04 (-0.16%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

EQ Equillium
$27.05 /

+23.95 (+772.58%)

C Citi
$52.25 /

-0.39 (-0.74%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

07/01/20 Morgan Stanley
Karyopharm initiated with an Overweight at Morgan Stanley
06/23/20 JPMorgan
Karyopharm price target raised to $37 from $31 at JPMorgan
06/23/20 RBC Capital
Karyopharm price target raised to $30 from $28 at RBC Capital
05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

07/14/20 Piper Sandler
Tesla price target raised to $2,322 from $939 at Piper Sandler
07/13/20
Fly Intel: Top five analyst upgrades
07/13/20 Morgan Stanley
Morgan Stanley says Tesla's 'virtually unchallenged dominance' may be near end
07/13/20 Roth Capital
Tesla upgraded to Neutral at Roth Capital as Musk prepares Indian market entry
FIT Fitbit
$6.64 /

-0.175 (-2.57%)

06/19/20 Deutsche Bank
Fitbit acquisition completing remains base case at Deutsche Bank
11/27/19 Deutsche Bank
Second Fitbit suitor should limit downside if deal breaks, says Deutsche Bank
11/06/19 DA Davidson
Sonos rallies after DA Davidson calls 'natural acquisition target' for Apple
11/04/19 DA Davidson
Fitbit downgraded to Neutral from Buy at DA Davidson
HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

07/14/20 Credit Suisse
Hanesbrands upgraded to Outperform from Neutral at Credit Suisse
07/14/20 Credit Suisse
Hanesbrands upgraded to Outperform from Neutral at Credit Suisse
06/24/20 B. Riley FBR
Hanesbrands products largely sold out at Walmart and Target, says B. Riley FBR
04/01/20
Fly Intel: Top five analyst initiations
INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
EQ Equillium
$27.05 /

+23.95 (+772.58%)

07/14/20 H.C. Wainwright
Equillium price target raised to $24 from $14 at H.C. Wainwright
07/10/20 Stifel
Equillium transferred with Buy rating, $10 target at Stifel
01/03/20 Stifel
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
SPOT Spotify
$261.11 /

-17.08 (-6.14%)

07/14/20 UBS
Spotify double-downgraded to Sell from Buy at UBS
07/14/20 UBS
Spotify downgraded to Sell from Buy at UBS
07/13/20 BofA
Spotify price target raised to $357 from $185 at BofA
07/06/20
Fly Intel: Top five analyst downgrades
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

07/09/20 Wolfe Research
JPMorgan upgraded to Outperform from Peer Perform at Wolfe Research
07/09/20 DA Davidson
JPMorgan upgraded to Buy from Neutral at DA Davidson
07/08/20 Seaport Global
JPMorgan initiated with a Buy at Seaport Global
06/23/20 Wells Fargo
Finicity should help MasterCard with open banking efforts, says Wells Fargo
C Citi
$52.25 /

-0.39 (-0.74%)

07/08/20 Seaport Global
Citi initiated with a Buy at Seaport Global
07/07/20 Societe Generale
Societe Generale upgrades BofA, Citi to Buy on 'path to respectability'
07/07/20 Societe Generale
Citi upgraded to Buy from Hold at Societe Generale
07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

07/10/20 Baird
Wells Fargo upgraded to Outperform from Neutral at Baird
07/09/20 Wolfe Research
Wells Fargo upgraded to Peer Perform from Underperform at Wolfe Research
07/08/20 JPMorgan
Wells Fargo price target lowered to $29.50 from $32 at JPMorgan
07/08/20 Seaport Global
Wells Fargo initiated with a Neutral at Seaport Global
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

EQ Equillium
$27.05 /

+23.95 (+772.58%)

C Citi
$52.25 /

-0.39 (-0.74%)

  • 14
    Jul
  • 04
    Mar
  • 14
    Feb
  • 09
    Jan
WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

C Citi
$52.25 /

-0.39 (-0.74%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

VRCA Verrica Pharmaceuticals
$8.80 /

-0.71 (-7.47%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

KPTI Karyopharm
$17.83 /

-1.33 (-6.94%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

WFC Wells Fargo
$25.43 /

-0.04 (-0.16%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

SPOT Spotify
$261.11 /

-17.08 (-6.14%)

JPM JPMorgan
$97.66 /

+1.35 (+1.40%)

HBI Hanesbrands
$11.47 /

+0.035 (+0.31%)

FIT Fitbit
$6.64 /

-0.175 (-2.57%)

C Citi
$52.25 /

-0.39 (-0.74%)

TSLA Tesla
$1,493.85 /

-53.69 (-3.47%)

Syndicate
Osmotica Pharmaceuticals 5M share Spot Secondary priced at $6.55 » 06:09
07/14/20
07/14
06:09
07/14/20
06:09
OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

The deal range was…

The deal range was $6.55-$7.33. Credit Suisse acted as sole book running manager for the offering.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

  • 14
    Jul
  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

On The Fly
Fly Intel: After-Hours Movers » 18:58
07/13/20
07/13
18:58
07/13/20
18:58
INMB

INmune Bio

$8.74 /

+1.72 (+24.50%)

, VNDA

Vanda Pharmaceuticals

$11.37 /

-0.125 (-1.09%)

, FREQ

Frequency Therapeutics

$20.43 /

-2.4 (-10.51%)

, EW

Edwards Lifesciences

$67.18 /

-0.67 (-0.99%)

, BA

Boeing

$175.62 /

-2.825 (-1.58%)

, OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

, ALT

Altimmune

$24.88 /

+2.56 (+11.47%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

03/12/20 H.C. Wainwright
INmune Bio price target lowered to $8 from $11 at H.C. Wainwright
03/11/20 Roth Capital
INmune makes progress in all programs, novel COVID-19 approach,says Roth Capital
12/18/19 Roth Capital
INmune Bio initiated with a Buy at Roth Capital
08/21/19
Fly Intel: Top five analyst initiations
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

06/09/20 Citi
Vanda downgraded to Neutral on FDA dispute at Citi
06/09/20 Citi
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi
03/16/20
Fly Intel: Top five analyst downgrades
03/16/20 Oppenheimer
Vanda Pharmaceuticals downgraded to Underperform at Oppenheimer on Hetlioz risks
FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

06/05/20 Piper Sandler
Post points to Edwards resuming recruiting for CLASP trial, says Piper Sandler
04/28/20 Wells Fargo
Edwards Lifesciences downgraded on sales growth gap at Wells Fargo
04/28/20 Wells Fargo
Edwards Lifesciences downgraded to Equal Weight from Overweight at Wells Fargo
04/27/20 Barclays
Edwards Lifesciences price target lowered to $155 from $165 at Barclays
BA Boeing
$175.62 /

-2.825 (-1.58%)

07/09/20
Emirates tells Bloomberg Boeing 777X likely to miss 2021 debut
07/08/20 Bernstein
Bernstein downgrades Spirit AeroSystems on slower delivery recovery
06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
ALT Altimmune
$24.88 /

+2.56 (+11.47%)

06/01/20 Roth Capital
Altimmune surprises with differentiated T-COVID study, says Roth Capital
05/06/20 Roth Capital
Novo data 'sets up the runway' for Altimmune, says Roth Capital
04/01/20
Roth Capital biotech analyst to hold an analyst/industry conference call
VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

INMB INmune Bio
$8.74 /

+1.72 (+24.50%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

  • 14
    Jul
  • 14
    Jul
  • 09
    Jan
  • 03
    Oct
EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

VNDA Vanda Pharmaceuticals
$11.37 /

-0.125 (-1.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

EW Edwards Lifesciences
$67.18 /

-0.67 (-0.99%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

FREQ Frequency Therapeutics
$20.43 /

-2.4 (-10.51%)

BA Boeing
$175.62 /

-2.825 (-1.58%)

ALT Altimmune
$24.88 /

+2.56 (+11.47%)

Syndicate
Osmotica Pharmaceuticals files to sell 5M ordinary shares » 16:15
07/13/20
07/13
16:15
07/13/20
16:15
OSMT

Osmotica Pharmaceuticals

$7.71 /

-1.06 (-12.09%)

Credit Suisse Securities…

Credit Suisse Securities will act as sole bookrunner for the proposed offering.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

07/10/20 Truist
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust
07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$7.71 /

-1.06 (-12.09%)

Recommendations
Osmotica Pharmaceuticals price target raised to $11 from $8 at SunTrust » 09:16
07/10/20
07/10
09:16
07/10/20
09:16
OSMT

Osmotica Pharmaceuticals

$7.01 /

+0.67 (+10.57%)

SunTrust analyst Gregory…

SunTrust analyst Gregory Fraser raised the firm's price target on Osmotica Pharmaceuticals to $11 from $8 and keeps a Buy rating on the shares after the company received FDA approval for Upneeq in ptosis, or "droopy eyelid". RVL-1201 becomes the first non-invasive treatment approved for this "prevalent" condition, the analyst tells investors in a research note, adding that "importantly", the label does not include a limitation on duration of use.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$7.01 /

+0.67 (+10.57%)

OSMT Osmotica Pharmaceuticals
$7.01 /

+0.67 (+10.57%)

07/09/20 RBC Capital
Osmotica price target raised to $12 from $10 at RBC Capital
03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
03/18/20 Truist
Osmotica Pharmaceuticals initiated with a Buy at SunTrust
OSMT Osmotica Pharmaceuticals
$7.01 /

+0.67 (+10.57%)

  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$7.01 /

+0.67 (+10.57%)

Recommendations
Osmotica price target raised to $12 from $10 at RBC Capital » 13:02
07/09/20
07/09
13:02
07/09/20
13:02
OSMT

Osmotica Pharmaceuticals

$6.74 /

+0.4 (+6.31%)

RBC Capital analyst…

RBC Capital analyst Randall Stanicky raised the firm's price target on Osmotica Pharmaceuticals to $12 from $10 and reiterates an Outperform rating on the shares after the company hosted a call this morning to discuss FDA approval and commercial plans for lead product Upneeq for blepharoptosis. Osmotica unveiled new details around its commercial strategy for Upneeq, beginning with implementation of an "early experience" program next month, Stanicky tells investors in a research note. The analyst raised his 2024 peak sales modestly higher to $339M and continues to "like the story here" ahead of launch uptake.

ShowHide Related Items >><<
OSMT Osmotica Pharmaceuticals
$6.74 /

+0.4 (+6.31%)

OSMT Osmotica Pharmaceuticals
$6.74 /

+0.4 (+6.31%)

03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
03/18/20 Truist
Osmotica Pharmaceuticals initiated with a Buy at SunTrust
03/06/20
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$6.74 /

+0.4 (+6.31%)

  • 09
    Jan
OSMT Osmotica Pharmaceuticals
$6.74 /

+0.4 (+6.31%)

On The Fly
Fly Intel: Pre-market Movers » 09:02
07/09/20
07/09
09:02
07/09/20
09:02
DSS

Document Security

$6.45 /

+0.3 (+4.88%)

, OSMT

Osmotica Pharmaceuticals

$6.34 /

-0.06 (-0.94%)

, GPL

Great Panther Mining

$0.57 /

+0.0321 (+5.94%)

, HELE

Helen of Troy

$195.37 /

+3.955 (+2.07%)

, EXFO

Exfo

$3.24 /

+0.1 (+3.18%)

, WBA

Walgreens Boots Alliance

$42.26 /

+0.03 (+0.07%)

, BBBY

Bed Bath & Beyond

$10.40 /

+0.15 (+1.46%)

, FSLY

Fastly

$96.15 /

+8.59 (+9.81%)

, HQY

HealthEquity

$59.15 /

+0.95 (+1.63%)

, OTIC

Otonomy

$3.58 /

+0.01 (+0.28%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OSMT Osmotica Pharmaceuticals
$6.34 /

-0.06 (-0.94%)

HQY HealthEquity
$59.15 /

+0.95 (+1.63%)

HELE Helen of Troy
$195.37 /

+3.955 (+2.07%)

GPL Great Panther Mining
$0.57 /

+0.0321 (+5.94%)

FSLY Fastly
$96.15 /

+8.59 (+9.81%)

EXFO Exfo
$3.24 /

+0.1 (+3.18%)

DSS Document Security
$6.45 /

+0.3 (+4.88%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

DSS Document Security
$6.45 /

+0.3 (+4.88%)

06/24/20 Aegis
Document Security assumed with a Buy at Aegis
10/10/19 Aegis
Document Security initiated with a Buy rating at Aegis
OSMT Osmotica Pharmaceuticals
$6.34 /

-0.06 (-0.94%)

03/23/20 Wells Fargo
Wells Fargo downgrades Osmotica to Equal Weight, halves price target to $4
03/23/20 Wells Fargo
Osmotica Pharmaceuticals downgraded to Equal Weight from Overweight at Wells Fargo
03/18/20 Truist
Osmotica Pharmaceuticals initiated with a Buy at SunTrust
03/06/20
Fly Intel: Top five analyst initiations
GPL Great Panther Mining
$0.57 /

+0.0321 (+5.94%)

05/11/20 Noble Capital
Great Panther Silver downgraded to Market Perform from Outperform at Noble Capital
01/15/20 Noble Capital
Great Panther Silver upgraded to Outperform from Market Perform at Noble Capital
12/02/19 Noble Capital
Great Panther Silver downgraded to Market Perform from Outperform at Noble Capital
HELE Helen of Troy
$195.37 /

+3.955 (+2.07%)

06/23/20 CL King
Helen of Troy price target raised to $210 from $170 at CL King
06/10/20 Oppenheimer
Helen of Troy price target raised to $200 from $185 at Oppenheimer
04/30/20 Oppenheimer
Helen of Troy price target raised to $185 from $175 at Oppenheimer
04/08/20 Oppenheimer
Helen of Troy price target lowered to $175 from $210 at Oppenheimer
EXFO Exfo
$3.24 /

+0.1 (+3.18%)

07/09/20 B. Riley FBR
EXFO results positive for Viavi and Dasan, says B. Riley FBR
WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

07/02/20 Morgan Stanley
Morgan Stanley lowers Walgreens price target to $45 ahead of earnings
06/29/20 Lake Street
Option Care Health should be bought on S-3 filing dip, says Lake Street
06/04/20 Mizuho
Walgreens Boots Alliance price target lowered to $48 from $53 at Mizuho
05/19/20 Cowen
Walgreens Boots Alliance price target lowered to $48 from $54 at Cowen
BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
FSLY Fastly
$96.15 /

+8.59 (+9.81%)

07/09/20 Citi
Citi recommends overweight Zoom Video, underweight Fastly pair trade
07/09/20 Citi
Citi downgraded Fastly to Sell with stock up 400% in three months
07/09/20 Citi
Fastly downgraded to Sell from Neutral at Citi
07/06/20 Piper Sandler
Fastly downgraded to Neutral from Overweight at Piper Sandler
HQY HealthEquity
$59.15 /

+0.95 (+1.63%)

06/03/20 Barrington
HealthEquity earnings selloff a buying opportunity, says Barrington
06/03/20 Cantor Fitzgerald
HealthEquity price target lowered to $70 from $80 at Cantor Fitzgerald
04/14/20 Guggenheim
Guggenheim starts HealthEquity at Buy with $56 price target
04/14/20 Guggenheim
HealthEquity initiated with a Buy at Guggenheim
OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OSMT Osmotica Pharmaceuticals
$6.34 /

-0.06 (-0.94%)

HQY HealthEquity
$59.15 /

+0.95 (+1.63%)

HELE Helen of Troy
$195.37 /

+3.955 (+2.07%)

GPL Great Panther Mining
$0.57 /

+0.0321 (+5.94%)

FSLY Fastly
$96.15 /

+8.59 (+9.81%)

EXFO Exfo
$3.24 /

+0.1 (+3.18%)

DSS Document Security
$6.45 /

+0.3 (+4.88%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

  • 09
    Jul
  • 09
    Jul
  • 02
    Jul
  • 22
    May
  • 21
    May
  • 21
    Feb
  • 09
    Jan
  • 10
    Jul
WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OSMT Osmotica Pharmaceuticals
$6.34 /

-0.06 (-0.94%)

HQY HealthEquity
$59.15 /

+0.95 (+1.63%)

HELE Helen of Troy
$195.37 /

+3.955 (+2.07%)

FSLY Fastly
$96.15 /

+8.59 (+9.81%)

EXFO Exfo
$3.24 /

+0.1 (+3.18%)

DSS Document Security
$6.45 /

+0.3 (+4.88%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

WBA Walgreens Boots Alliance
$42.26 /

+0.03 (+0.07%)

FSLY Fastly
$96.15 /

+8.59 (+9.81%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.